Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-9

  Goletti, Delia ^a   Raja, Alamelu ^b   Kabeer, Basirudeen Syed Ahamed ^b   Rodrigues, Camilla ^c   Sodha, Archana ^c   Carrara, Stefania ^a   Vernet, Guy ^d   Longuet, Christophe ^d   Ippolito, Giuseppe ^a   Thangaraj, Satheesh ^e   Leportier, Marc ^e   Girardi, Enrico ^a   Lagrange, Philippe Henri ^f  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c P D HINDUJA NATIONAL HOSPITAL   (India)

^d Fondation Merieux   (France)

^e BIOMÉRIEUX   (France)

^f SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; MITOGENIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 2; REGION OF DIFFERENCE ANTIGEN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOASSAY; INDIA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; AIDS RELATED COMPLEX; BLOOD;

MYCOBACTERIUM TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BIOLOGICAL MARKERS; CHEMOKINE CCL8; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-2; MALE; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 77958585706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012577     Document Type: Article

References (39)

1. Getahun H, Gunneberg C, Granich R, Nunn P (2010) HIV Infection-Associated Tuberculosis: The Epidemiology and the Response. Clin Infecti Dis 50: S201-S207.
2. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375: 1920-37.
3. Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-84.
4. Lange C, Mori T (2010) Advances in the diagnosis of tuberculosis. Respirology 15: 220-40.
5. Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, et al. (2007) Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 150: 91-8.
6. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, et al. (2010) Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4 + T-cells in HIV infection. Eur Respir J 35: 619-26.
7. Syed Ahamed Kabeer B, Raman B, Thomas A, Perumal V, Raja A (2010) Role of QuantiFERON-TB gold, interferon c inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5: e9051.
8. Ahamed Kabeer B, Sikhamani R, Swaminathan S, Perumal V, Paramasivam P, et al. (2009) Role of interferon c release assay in active TB diagnosis among HIV infected individuals. PLoS One 4: e5718.
9. Goletti D, Carrara S, Vincenti D, Girardi E (2007) T-cell responses to commercial mycobacterium tuberculosis-specific antigens in HIV-infected patients. Clin Infect Dis 45: 1652-4.
10. Goletti D, Toossi Z (2009) Immunological profiles of tuberculosis patients coinfected with HIV-1. In: Tomioka H, editor. Research Signpost, Kerala, India. pp.141-166.
11. Hoffmann M, Ravn P (2010) The use of Interferon-c release assays in HIVpositive individuals. Eur Inf Dis 4: 23-9.
12. Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, et al. (2003) Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med 9: 105-11.
13. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, et al. (2005) Selected RD1 peptides for active tuberculosis diagnosis: comparison of a c interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 12: 1311-6.
14. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, et al. (2004) Use of a T-cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38: 754-6.
15. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, et al. (2008) Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis e28: 11.
16. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, et al. (2006) Region of difference 1 antigen-specific CD4 + memory T-cells correlate with a favorable outcome of tuberculosis. J Infect Dis 194: 984-92.
17. Goletti D, Carrara S, Butera O, Amicosante M, Ernst M, et al. (2008) Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS ONE 3: e3417.
18. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, et al. (2007) Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res e8: 5.
19. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, et al. (2006) Human Tcell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8: 2052-2060.
20. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, et al. (2010) Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 36: 1-8.
21. Lawn SD, Bangani N, Vogt M, Bekker LG, Badri M, et al. (2007) Utility of interferon-c ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis e7: 99.
22. Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, et al. (2007) Discrepancy between Mycobacterium tuberculosis-specific c interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14: 880-5.
23. Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, et al. (2009) New tools for detecting latent tuberculosis infection: Evaluation of RD1-specific long-term response. BMC Infect Dis 9: 182.
24. Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, et al. (2007) Dynamic relationship between IFN-c and IL-2 profile of Mycobacterium tuberculosis-specific T-cells and antigen load. J Immunol 178: 5217-5226.
25. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, et al. (2010) Detection of IL-2 in addition to IFN-c discriminates active tuberculosis patients, latently infected individuals and controls. Clin Microbiol Infect. In press.
26. Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, et al. (2009) Cytometric detection of antigen-specific IFN-c/IL-2 secreting cells in the diagnosis of tuberculosis. BMC Infect Dis 9: 99.
27. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, et al. (2008) Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 32: 1607-15.
28. Ruhwald M, Petersen J, Kofoed K, Nakaoka H, Cuevas LE, et al. (2008) Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One3: e2858.
29. Whittaker E, Gordon A, Kampmann B (2008) Is IP-10 a better biomarker for active and latent tuberculosis in children than IFN-c? PLoS One 3: e3901.
30. Moser B, Loetscher P (2001) Lymphocyte traffic control by chemokines. Nat Immunol 2: 123-128.
31. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, et al. (2005) IFN-c-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7: 1-8.
32. Berktas M, Guducuoglu H, Bozkurt H, Onbasi KT, Kurtoglu MG, et al. (2004) Change in serum concentrations of interleukin-2 and interferon-c during treatment of tuberculosis. J Int Med Res 32: 324-30.
33. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare (2009) Revised National Tuberculosis Control Programme manual for laboratory technicians. Ministry of Health and Family Welfare, New Delhi, India [http://www.tbcindia.org/LABMANUAL.pdf].
34. Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, et al. (2010) IFN-c, but not IP10, MCP2 or IL2 response to RD1 selected peptides associates to active tuberculosis. J Infect 61: 133-43.
35. Kabeer BS, Sikhamani R, Raja A (2010) Comparison of interferon-c and interferon c-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 24: 323-5.
36. Harada N, Higuchi K, Sekiya Y, Rothel J, Kitoh T, et al. (2004) Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tuberculosis infection with the use of Mycobacterium tuberculosis-specific antigens, ESAT-6 and CFP-10. Kekkaku 79: 725-735.
37. Centers for Disease Control and Prevention (2010) Updated guidelines for using IFN-c release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR, 59 (No. RR-5): 1-25.
38. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, et al. (2009) T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 13: 84-92.
39. Chadha VK, Jagannatha PS, Vaidyanathan PS, Jagota P (2003) PPD RT23 for tuberculin surveys in India. Int J Tuberc Lung Dis 7: 172-9.